Aurora Innovation, Inc. (NASDAQ: AUR) today announced David Maday, Chief Financial Officer, will participate in a virtual ...

Canaccord Genuity has downgraded Pliant (PLRX) to hold following news that the company has paused a clinical trial for its ...

In a report released yesterday, Alexander Bedwany from Canaccord Genuity reiterated a Buy rating on Kodal Minerals (KOD – Research Report), ...

Canaccord Genuity analyst Alexander Bedwany reiterated a Sell rating on South32 Ltd. (S32 – Research Report) yesterday and set a price target ...

Fintel reports that on February 10, 2025, Canaccord Genuity downgraded their outlook for Pliant Therapeutics (NasdaqGS:PLRX) ...

Vertex Pharmaceuticals (VRTX) stock gets an upgrade from Canaccord Genuity after its Q4 2024 results on Tuesday, Read more here.

The surprise retirement of Dunelm's boss shouldn't put off investors from the homeware retailer's strong growth prospects, ...

Canopy Growth (TSE:WEED – Get Free Report) had its target price decreased by analysts at Canaccord Genuity Group from C$2.50 to C$1.50 in a research report issued to clients and investors on ...

Pliant Therapeutics (NASDAQ:PLRX – Get Free Report)‘s stock had its “hold” rating restated by research analysts at Canaccord Genuity Group in a note issued to investors on Monday, MarketBeat reports.

Canaccord Genuity revised its price target for Cybin Inc. (NYSE:CYBN) shares, reducing it to $73.00 from the previous $86.00, ...

A big dividend yield for a few years doesn't mean much if it can't be sustained. While Canaccord Genuity Group is not profitable, it is paying out less than 75% of its free cash flow, which means ...